Israel Englander Contrafect Corp Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $500,871 - $695,567	-157,013 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $562,106 - $769,363	157,013 New	157,013 $691,000
Q1 2021 May 17, 2021	SELL	$4.46 - $6.68 $114,537 - $171,549	-25,681 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.05 - $6.4 $129,689 - $164,358	25,681 New	25,681 $130,000
Q2 2020 Aug 14, 2020	SELL	$4.69 - $7.81 $335,203 - $558,196	-71,472 Closed	0 $0

Q1 2020 May 14, 2020	BUY	$5.5 - $12.3 $393,096 - $879,105	71,472 New	71,472 $412,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.